Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Pfizer begins Phase II trial of PF-06252616 to treat duchenne muscular dystrophy Pfizer has started patient enrollment in a multicenter Phase II clinical trial of PF-06252616, an experimental, infused, anti-myostatin monoclonal antibody, to treat Duchenne muscular dystrophy (DMD). Contract Research & Services > Clinical Trials > News
iCardiac Technologies IQ-CSRC study shows potential for faster drug development The Food and Drug Administration hosted the Cardiac Safety Research Consortium (CSRC) meeting to release the results of the IQ-CSRC Study demonstrating the ability to conduct robust cardiac safety characterization several years earlier in clinical development.
News NutraFuels receives purchase order from RC Taylor distributing NutraFuels, manufacturer of oral spray dietary supplements, announced that the company has received and fulfilled its first purchase order from R.C. Taylor Distributing.
News Iodine launches cold and flu app to helps smart consumers find best OTC options for their symptoms Iodine, a developer of health information website Iodine.com, has launched a new web app for cold and flu season.
News
BioBlast receives notice of patent issuance for new fusion protein-based platform to treat Friedrich's Ataxia Bio Blast Pharma a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today it has received a Notice of Patent Issuance for patent no. 8,912,147 from the US Patent and Trademark Office (USPTO) for a composition-of-matter patent for its novel fusion protein for Friedrich's Ataxia (referred to as BB-FA) that is built on its mitochondrial protein replacement (mPRT) platform.
News CannaPharmaRx, PharmaDirections to start research & discovery program in Cannabinoid Science CannaPharmaRx, the New Jersey-based pharmaceutical company, will be working with PharmaDirections, a pharmaceutical project management and consulting group, as it launches its R&D platform to investigate product opportunities in endocannabinoid science for ultimate commercialization in global markets.
News Clementia begins natural history trial in FOP patients By PBR Staff Writer
Clementia Pharmaceuticals has started a natural history trial in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease.
News

Latest News and Insight by Sector

Production & Manufacturing

NutraFuels receives purchase order from RC Taylor distributing
NutraFuels, manufacturer of oral spray dietary supplements, announced that the company has received and fulfilled its first purchase order from R.C. Taylor Distributing.
News
Iodine launches cold and flu app to helps smart consumers find best OTC options for their symptoms
Iodine, a developer of health information website Iodine.com, has launched a new web app for cold and flu season.
News

Drug Research

iCardiac Technologies IQ-CSRC study shows potential for faster drug development
The Food and Drug Administration hosted the Cardiac Safety Research Consortium (CSRC) meeting to release the results of the IQ-CSRC Study demonstrating the ability to conduct robust cardiac safety characterization several years earlier in clinical development.
News
BioLineRx, Novartis to develop and commercialize Israeli-sourced drug candidates
By PBR Staff Writer
Clinical-stage biopharmaceutical company BioLineRx and Novartis Pharma have reached a multi-year strategic collaboration agreement to support the development and commercialization of Israeli-sourced drug candidates.
News

Inward Investment

Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn
By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
News
Endo International to buy Auxilium Pharmaceuticals for $2.6bn
By PBR Staff Writer
Ireland-based Endo International has signed an agreement to acquire Auxilium Pharmaceuticals, in a deal that is worth nearly $2.6bn.
News

Packaging

Eisai opens new packaging facility at UK's Hatfield production plant
By PBR Staff Writer
Eisai has opened a new packaging facility at its Hatfield, Hertfordshire production plant in the UK, ahead of plans to launch new products.
News
Packaging Coordinators completes acquisition of Biotec
By PBR Staff Writer
Packaging services provider Packaging Coordinators (PCI) has completed the acquisition of UK-based pharmaceutical services provider Biotec for an undisclosed amount.
News

Contract Research & Services

CannaPharmaRx, PharmaDirections to start research & discovery program in Cannabinoid Science
CannaPharmaRx, the New Jersey-based pharmaceutical company, will be working with PharmaDirections, a pharmaceutical project management and consulting group, as it launches its R&D platform to investigate product opportunities in endocannabinoid science for ultimate commercialization in global markets.
News
Clementia begins natural history trial in FOP patients
By PBR Staff Writer
Clementia Pharmaceuticals has started a natural history trial in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease.
News

Automation

BioBlast receives notice of patent issuance for new fusion protein-based platform to treat Friedrich's Ataxia
Bio Blast Pharma a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today it has received a Notice of Patent Issuance for patent no. 8,912,147 from the US Patent and Trademark Office (USPTO) for a composition-of-matter patent for its novel fusion protein for Friedrich's Ataxia (referred to as BB-FA) that is built on its mitochondrial protein replacement (mPRT) platform.
News
Halozyme, Janssen to develop and commercialize products using Enhanze technology
By PBR Staff Writer
US-based biopharmaceutical firm Halozyme Therapeutics has entered into a worldwide collaboration and license agreement with Janssen Biotech to develop and commercialize products combining Janssen compounds with Halozyme's Enhanze technology.
News

Regulatory Affairs

FDA accepts filing Apotex's biosimilar application for pegfilgrastim
By PBR Staff Writer
The US Food and Drug Administration has accepted for filing Canadian pharmaceutical firm Apotex's application for pegfilgrastim, a biosimilar version of Amgen's Neulasta.
News
NICE recommends Boehringer's Pradaxa to treat and prevent recurrence of DVT and PE
By PBR Staff Writer
The UK's National Institute for Health and Care Excellence (NICE) has granted approval for Boehringer Ingelheim's dabigatran etexilate (Pradaxa) for use by the National Health Service to treat and prevent the recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
News

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Reports Buy online from $250



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery